Klivira
Request demo

Automating Pediatric Oncology Oncology Pathways Prior Auth

Navigating the complexities of pediatric oncology oncology pathways prior auth demands precision and speed. Klivira automates this critical process, ensuring timely access to life-saving treatments for childhood cancer patients.

Revenue cycle directors and prior authorization coordinators in pediatric oncology face unique challenges. The specialized nature of childhood cancer treatments, often guided by intricate protocols, necessitates a robust and efficient prior authorization workflow to prevent delays in care. Klivira's platform is engineered to address these specific demands.

The Unique Landscape of Pediatric Oncology Prior Authorization

Pediatric oncology involves highly specialized, often multi-modal treatment plans, frequently adhering to Children's Oncology Group (COG) protocols. These regimens, including complex chemotherapy sequences, CAR-T cell therapies, and advanced radiation like proton beam therapy, represent significant PA triggers due to their cost and complexity. Ensuring swift approval is paramount to avoid critical treatment delays for a vulnerable patient population.

High-Volume PA Categories in Pediatric Oncology

  • Multi-agent chemotherapy regimens dictated by COG protocols.
  • Novel cellular therapies, including CAR-T cell therapy.
  • Advanced radiation modalities such as proton beam therapy.
  • Specialty medications and targeted therapies.
  • High-resolution diagnostic imaging (e.g., PET/CT for staging and response).
  • Surgical procedures integral to treatment plans.

Integrating Evidence-Based Pathways with PA Workflows

While NCCN guidelines are prominent in adult oncology, pediatric oncology pathways often align with COG protocols and other evidence-based clinical guidelines. Klivira's platform facilitates the submission of comprehensive documentation, including detailed COG protocol information and clinical rationale, to validate treatment alignment with payer-specific or nationally recognized pathways. This ensures that regimen submissions are complete and accurate from the outset.

Streamlining EMR and Payer Touchpoints

Effective prior authorization in pediatric oncology requires seamless integration with EMR systems and diverse payer channels. Klivira connects directly to EMR order sets for chemotherapy, radiation, and specialty medications, extracting necessary clinical data (ePHI) while maintaining HIPAA compliance. This data is then formatted for efficient submission via X12 278 transactions, ePA platforms (NCPDP SCRIPT), or direct payer portal automation, reducing manual data entry and improving submission accuracy.

Expediting Approvals for Critical Therapies

For therapies like CAR-T and proton beam therapy, which are often time-sensitive and require specialized reviews, Klivira accelerates the prior authorization process. By automating regimen submission and pathway validation, our platform helps reduce the administrative burden on PA coordinators, allowing them to focus on complex cases and appeals. This translates to faster approvals and improved patient access to critical, life-saving treatments.

Frequently asked questions

How does Klivira handle prior authorization for COG-protocol chemotherapy?

Klivira integrates with your EMR to extract relevant patient and protocol data directly from COG-specific order sets and clinical documentation. We then structure this information to meet payer requirements for regimen submission and pathway validation, expediting the authorization process for these complex treatment plans.

Can Klivira support prior authorization for CAR-T cell therapies in pediatric oncology?

Yes, Klivira is designed to manage high-cost, high-complexity therapies like CAR-T. Our platform automates the submission of required clinical documentation, including genetic testing results and treatment plans, ensuring payers have the necessary information for a swift review and approval.

What EMR data points are typically required for pediatric oncology prior auth?

Key data points include patient demographics, ICD-10-CM diagnoses, CPT codes for procedures and treatments, detailed chemotherapy regimens (drug, dose, frequency), radiation therapy plans, imaging reports, pathology results, and clinical notes supporting medical necessity. Klivira's EMR integration automates the extraction of this ePHI.

How does Klivira ensure compliance with payer-specific oncology pathways?

Klivira maintains an extensive library of payer-specific rules and pathways, including those applicable to pediatric oncology. Our system cross-references submitted regimens and clinical data against these rules, flagging potential discrepancies before submission to ensure alignment and reduce denials.

Is Klivira compatible with existing ePA and X12 278 workflows for pediatric oncology?

Absolutely. Klivira leverages industry-standard protocols, including X12 278 for electronic prior authorization submission and status checks, and integrates with ePA platforms using NCPDP SCRIPT. This ensures seamless communication with payers regardless of their preferred electronic channel.

Related coverage

Other pediatric-oncology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo